This study presents bioassays for CBD, which can be used to assess the neurotrophic bioactivity of CBD formulations.
Pedro P. Perez
Advertisement
Articles by Pedro P. Perez
Advertisement
Latest Updated Articles
Advertisement
Advertisement
- News
- Multimedia
- Columns
- Publications
- Webcasts
- Resources
- Subscribe
- Advocates
- Analytical Methods
- Auto-immune Diseases
- Breast Cancer
- CBD
- COVID-19
- Cannabinoids
- Cannabis Perspectives
- Cannabis Strains
- Caregivers
- Chromatography Techniques
- Chronic Pain
- Consensus Methods
- Contaminants
- Cultivation
- Doctors
- Edibles
- Extraction
- GC-MS
- Gas Chromatography (GC)
- Government
- Growers and Growing
- HPLC and UHPLC
- Healthcare
- Hemp
- ICP-MS
- International Updates
- LC-MS
- Laboratory Accreditation
- Laboratory Best Practices
- Legal Issues
- Manufacturing
- Mass Spectrometry
- Medical Cannabis
- Medical Marijuana (MMJ)
- Mental Health
- Noid Factoid
- Nurses
- PTSD
- Patients
- Pediatric Cancer
- Pesticides
- Potency
- Processing
- Psychedelics
- Q&A with ASA: Meet the Chapters
- Quality Control and Quality Assurance
- Regulations and Regulatory Issues
- Research
- Sample Preparation
- Seizure Disorders
- Spectroscopy Techniques
- THC
- Terpenes
- Tetrahydrocannabinol (THC)
- Veterans